Intercept Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012 - 2010
Revenue	285.71	260.75	233.97	252	179.8	130.96	24.95	2.78	1.74	1.62	Upgrade
Revenue Growth (YoY)	9.57%	11.45%	-7.16%	40.15%	37.30%	424.85%	796.87%	59.70%	7.40%	-33.69%	Upgrade
Cost of Revenue	0.98	1.21	2.35	4.21	2.52	1.37	0	0	0	0	Upgrade
Gross Profit	284.73	259.55	231.62	247.79	177.29	129.59	24.95	2.78	1.74	1.62	Upgrade
Selling, General & Admin	176.3	177.49	260.5	317.42	255.47	273.7	273.6	119.24	34.6	13.13	Upgrade
Research & Development	176.64	182.75	189.03	242.8	207.3	191.5	153.89	112.7	80.31	27.94	Upgrade
Other Operating Expenses	0	-0.28	11.81	0	0	0	0	0	0	0	Upgrade
Operating Expenses	352.94	359.95	461.34	560.22	462.78	465.2	427.49	231.94	114.91	41.07	Upgrade
Operating Income	-68.22	-100.41	-229.73	-312.43	-285.49	-335.61	-402.54	-229.16	-113.17	-39.45	Upgrade
Interest Expense / Income	21.39	54.42	48.05	41.14	30.52	29.27	14.2	0	0	0	Upgrade
Other Expense / Income	-311.42	-63.4	-2.9	-8.89	-6.77	-4.52	-3.9	-2.73	170.06	28.34	Upgrade
Pretax Income	221.82	-91.43	-274.88	-344.68	-309.24	-360.37	-412.83	-226.43	-283.23	-67.79	Upgrade
Net Income	221.82	-91.43	-274.88	-344.68	-309.24	-360.37	-412.83	-226.43	-283.23	-67.79	Upgrade
Shares Outstanding (Basic)	34	32	33	32	28	25	25	24	21	18	Upgrade
Shares Outstanding (Diluted)	34	32	33	32	28	25	25	24	21	18	Upgrade
Shares Change	6.09%	-3.26%	4.16%	11.21%	13.61%	1.59%	4.09%	14.00%	15.28%	186.94%	Upgrade
EPS (Basic)	6.56	-2.87	-8.34	-10.89	-10.86	-14.38	-16.74	-9.56	-13.63	-3.76	Upgrade
EPS (Diluted)	6.56	-2.87	-8.34	-10.89	-10.86	-14.38	-16.74	-9.56	-13.63	-3.76	Upgrade
Free Cash Flow	-27.35	-41.46	-175.76	-237.75	-240.88	-275.79	-347.52	-168.84	-92.38	-29.64	Upgrade
Free Cash Flow Per Share	-0.81	-1.30	-5.33	-7.51	-8.46	-11.01	-14.09	-7.13	-4.45	-1.64	Upgrade
Gross Margin	99.66%	99.54%	98.99%	98.33%	98.60%	98.95%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-23.88%	-38.51%	-98.19%	-123.98%	-158.78%	-256.28%	-1613.31%	-8237.10%	-6496.56%	-2432.31%	Upgrade
Profit Margin	77.64%	-35.06%	-117.49%	-136.78%	-171.99%	-275.18%	-1654.56%	-8139.07%	-16258.67%	-4179.53%	Upgrade
Free Cash Flow Margin	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%	-210.60%	-1392.81%	-6068.91%	-5303.16%	-1827.07%	Upgrade
EBITDA	245.46	-29.48	-218.61	-294.49	-274.14	-326.5	-394.8	-224.74	-282.78	-67.69	Upgrade
EBITDA Margin	85.91%	-11.31%	-93.44%	-116.86%	-152.46%	-249.32%	-1582.31%	-8078.29%	-16233.24%	-4173.00%	Upgrade
Depreciation & Amortization	2.26	7.53	8.21	9.05	4.58	4.6	3.83	1.69	0.44	0.11	Upgrade
EBIT	243.2	-37.01	-226.83	-303.54	-278.72	-331.1	-398.63	-226.43	-283.23	-67.79	Upgrade
EBIT Margin	85.12%	-14.19%	-96.95%	-120.45%	-155.01%	-252.83%	-1597.67%	-8139.07%	-16258.67%	-4179.53%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).